There's no way to cheat death, but science shows there may be better ways to go than others. DailyMail.com reveals the most ...

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory ...

Addressing patients with chronic kidney disease requires a commitment to data, education, and community, specifically in those affected by social determinants of health (SDOH).

The FDA on Thursday approved Fabhalta (iptacopan) to treat complement 3 glomerulopathy (CG3), a progressive, ultrarare kidney ...

This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.

Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts spotted several shortfalls in the drug's label, leaving more to be desired—and ...

The FDA approved oral iptacopan (Fabhalta; Novartis) to reduce proteinuria in adults with C3 glomerulopathy (C3G), according ...

In patients with CKD, hyperkalemia significantly increases risk for major adverse cardiovascular events and arrhythmia.

Study findings support the monitoring and management of iron status in patients with early stages of chronic kidney disease (CKD).

Investigators assessed frailty prevalence in a nationally representative US cohort and inpatient outcomes among kidney transplant recipients.

The use of technicians to assist in delivering dialysis to the end-stage kidney disease population has been a recognized role ...